文献速递骨质疏松与代谢性骨病创伤骨科

长期吸入糖皮质激素对老年女性脆性骨折的影响:Manitoba BMD注册研究

Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study.
PubMed 文献 · Osteoporos Int · 2020-03-02

该研究基于Manitoba BMD注册(1996-2013)纳入6880名≥40岁患哮喘或COPD的老年女性,平均随访7.7年,发现长期吸入糖皮质激素(ICS)使用与主要骨质疏松性骨折风险增加无关。

要点

  • 长期ICS使用未增加老年女性主要骨质疏松性骨折风险。
  • 不同暴露分层(发放天数、数量、MPR、年均剂量)均无显著关联。
  • 该人群平均随访7.7年,12%发生主要骨质疏松性骨折。

核心结论

  • 长期ICS使用不增加老年慢性呼吸疾病女性主要骨质疏松性骨折风险。

研究设计与样本

  • 基于Manitoba健康行政数据库与BMD注册的回顾性队列研究,纳入6880名≥40岁患哮喘或COPD的女性,平均随访7.7年。

主要发现

  • 6880名女性中810名(12%)发生主要骨质疏松性骨折。
  • 基线后12个月内ICS暴露分层(发放天数p=0.90;发放数量p=0.67)与骨折风险无关。
  • 整个随访期ICS暴露分层(MPR p=0.62;年均剂量p=0.58)与骨折风险无关。

临床怎么用

  • 对老年女性慢性呼吸疾病患者,长期ICS治疗时无需因骨折风险而过度担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The effects of inhaled corticosteroids (ICS) on fracture risk in older women with chronic respiratory diseases are not well established. Our results indicate long-term ICS use in this population does not increase the risk of major osteoporotic fracture. This finding further elucidates the long-term safety of ICS in older women. INTRODUCTION: Inhaled corticosteroids (ICS) are frequently used in older women with chronic respiratory diseases. There is insufficient evidence regarding the association between long-term ICS use and the risk of fragility fractures in this population. METHODS: We used linked Manitoba health administrative databases and the provincial bone mineral density (BMD) registry (1996-2013) to identify women ≥ 40 years of age with asthma and/or chronic obstructive pulmonary disease (COPD) within 3 years preceding the baseline BMD test. We followed them until the first major osteoporotic fracture or end of study, whichever came first. ICS use, stratified by exposure tertiles, was measured within the 12-month period following the baseline BMD test (by total days and quantity, primary outcome), and over the entire follow-up period (by medication possession ratio (MPR) and average annual dose, secondary outcome). The hazard ratio of fracture with ICS use was estimated using a Cox proportional hazards model, controlling for baseline determinants of fracture. RESULTS: Of 6880 older women with asthma (38%) or COPD (62%), 810 (12%) experienced a major osteoporotic fracture over a mean follow-up of 7.7 years (SD = 3.9). ICS use at any tertile was not associated with an increased risk of fracture (dispensed days, p = 0.90; dispensed quantity, p = 0.67). Similarly, ICS use at any tertile during the entire follow-up period was not associated with an increased risk of fracture (MPR, p = 0.62; average annual dose, p = 0.58). CONCLUSION: Our findings do not support an increased risk of major osteoporotic fracture in older women with chronic respiratory diseases due to long-term ICS use.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ng BC, Leslie WD, Johnson KM, et al. Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study. Osteoporos Int. 2020. PMID: 32123939. doi:10.1007/s00198-020-05361-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。